20240208171546.png)
Nominations are currently being sought for the Paul Marks Prize for Cancer Research. This award, established by Memorial Sloan-Kettering Cancer Center (MSKCC) in 2001, is named for Paul A. Marks, MD, President Emeritus of the Center and a distinguished scientist.
A new health policy report suggests that the swift and dramatic rise in cancer-drug spending is due to laws that keep Medicare from managing the use or price of cancer drugs. These laws limit Medicare's actions in cancer far more than they are limited in other areas of healthcare.
A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.
New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.
Memorial Sloan-Kettering Cancer Center (MSKCC) and Summit Medical Group (SMG) together announce a new collaborative relationship for the care of people with cancer. The initiative will give New Jersey residents who have cancer greater access to a broad array of services offered at both MSKCC and SMG.
American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan-Kettering Cancer Center (MSKCC).
New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection.
The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
The Society for Pediatric Radiology, which includes physicians from Memorial Sloan-Kettering Cancer Center (MSKCC), has launched a project known as Image Gently, which seeks to decrease unnecessary imaging and radiation levels in children.
A study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) has uncovered how breast tumors use a particular type of molecule to promote metastasis "“ the spread of cancer cells. Metastasis is the cause of approximately 90 percent of all cancer-related deaths. The study is published in the April 4, 2008, issue of Cell.
Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice. The study's results are published in the March 23 online edition of the journal Nature Medicine.
The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.
A new study led by researchers at Memorial Sloan-Kettering Cancer Center reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.
A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.
The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.
A $10 million commitment from James H. and Marilyn H. Simons through the Simons Foundation will support preclinical initiatives undertaken as part of Memorial Sloan-Kettering's new Brain Tumor Center (BTC).
Researchers have identified a specific group of microRNA molecules that are responsible for controlling genes that cause breast cancer metastasis. The study, led by scientists at Memorial Sloan-Kettering Cancer Center (MSKCC), appears in the January 10, 2008, issue of Nature.
Breast cancer risk varies widely among women who are carriers of the BRCA1 and BRCA2 mutations, according to a new study published in the January 9, 2008, issue of the Journal of the American Medical Association (JAMA).
A new study by researchers at Memorial Sloan-Kettering Cancer Center finds that even the sickest cancer patients are willing and able to "self-report" symptoms using the Internet, thus supplying key data in real time to their healthcare providers.
According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.
A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive. The study found that patients aged 65 to 69 years old who consult a urologist are more likely to undergo surgery to remove the prostate, while those who consult a radiation oncologist and a urologist, regardless of age, usually receive radiation therapy.
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.
Philanthropist and art collector Iris Cantor has made a major commitment to New York's Memorial Sloan-Kettering Cancer Center to create an endowed chair for a senior researcher in the field of digestive cancers. Mrs. Cantor is establishing the position with support totaling $2.5 million from the Iris and B. Gerald Cantor Foundation.
Biologists at Memorial Sloan-Kettering Cancer Center (MSKCC) have identified a set of genes expressed in human breast cancer cells that work together to remodel the network of blood vessels at the site of the primary tumor. These genes were also found to promote the spread of breast cancer to the lungs. The study, conducted in mice and reported in this week's Nature, helps to explain how cancer metastasis can occur and highlights targets for therapeutic treatment.
A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma "“ the most common and aggressive type of renal tumor "“ and arms the urologist with crucial information that will help determine whether surgery is needed.
The first report of an international study looking at computed tomography (CT) to screen current or former smokers for lung cancer found that screening did not reduce deaths from lung cancer. Although CT screening found nearly three times as many lung cancers as predicted, the researchers found that early detection and treatment did not lead to a corresponding decrease in advanced lung cancers or a reduction in deaths from lung cancer.
This new initiative is a five-year, nearly $2 million dollar federally-funded collaboration among Memorial Sloan-Kettering Cancer Center, the American Cancer Society's Queens office, the Queens Library and the Queens Cancer Center of Queens Hospital. The goal of this project, initiated by Memorial Sloan-Kettering Cancer Center, is to improve access to cancer screening and care in underserved communities.
PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon, and brain. Researchers led by scientists at Memorial Sloan-Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the January 12 issue of Cell.
Computational biology researchers today announced a new Internet tool for the exploration of the scientific literature in medicine and biology. The freely accessible iHOP service provides fast, accurate, comprehensive, and up-to-date summary information on more than 80,000 biological molecules by automatically extracting key sentences from millions of PubMed documents when a search is requested.
A foundation created by American billionaire, Daniel K. Ludwig, will this year give six leading US institutions $20 million cash each, plus stock in a New York real estate holding company, to create Ludwig Centers. The $120 million plus gift, with further distributions from the Ludwig Fund over the next six years, should ensure that each Ludwig Center receives annual research funds of approximately $2 million in perpetuity.
A gift from the estate of renowned fashion designer Geoffrey Beene will enable Memorial Sloan-Kettering Cancer Center (MSKCC) to launch an ambitious research initiative to be known as the Geoffrey Beene Cancer Research Center. It will build on MSKCC's strong existing scientific and clinical programs with the goal of translating the revolutionary advances researchers have made in understanding how cancer works at the cellular level into equally dramatic progress in controlling it.
Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.
The Starr Foundation today announced that it has made a $100 million grant to create a wide-ranging cancer consortium to coordinate the efforts of five internationally renowned research institutions in the fight against cancer. Joining this ambitious undertaking is The Broad Institute of MIT and Harvard, Cold Spring Harbor Lab, Memorial Sloan-Kettering Cancer Center, Rockefeller University and Weill Cornell Medical College.
Memorial Sloan-Kettering Cancer Center is now poised to take greater advantage of a new era in cancer research and education with the opening of a state-of-the-art research center, the establishment of a new graduate school, and the founding of a novel research program in human oncology.
A retrospective study by urologists at Memorial Sloan-Kettering Cancer Center (MSKCC) and their colleagues, suggests that this practice needs to be re-evaluated. Researchers add that with advances in imaging, almost 70 percent of kidney cancer patients have their tumor detected at a very small size, allowing surgeons to perform less radical surgery with superior results.
Memorial Sloan-Kettering Cancer Center (MSKCC) opened a new state-of-the-art outpatient cancer treatment facility in Basking Ridge, New Jersey, today. The new 85,000-square-foot facility incorporates the latest concepts in therapeutic design and offers the most advanced cancer care services.
The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions "” Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University "” has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.
Peter Scardino, MD, a urologic surgeon and internationally recognized authority on prostate cancer, has been named the new Chairman of the Department of Surgery at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Scardino, whose appointment became effective July 1, replaces the esteemed surgeon Murray Brennan, MD, who recently stepped down from the post after more than 20 years.
Memorial Sloan-Kettering Cancer Center (MSKCC) has opened a new 72,000-square-foot surgical center that was uniquely designed to take advantage of the latest medical technology while enhancing patient safety and efficiency of care.
A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.
According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.
Memorial Sloan-Kettering Cancer Center today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan-Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan-Kettering's history.
Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted in leukemia. The results will lead to a better understanding of the behavior of leukemic cells.
According to a study, women with Stage III ovarian cancer given a combination of intravenous and intra-abdominal chemotherapy, following the successful surgical removal of tumors, experienced a median survival time 16 months longer than women who received IV chemotherapy alone.
This research is the first to demonstrate a way to genetically correct sickle cell disease using RNA interference. The technique should be broadly applicable to use therapeutically in stem cells or malignant cells.
The Paul Marks Prize for Cancer Research Goes to Three Investigators Who Have Made Important Contributions to the Understanding of Disease.
A team of researchers led by scientists at Memorial Sloan-Kettering Cancer Center have discovered that a new class of drugs "” now in early stage clinical trials "” work best in patients with mutations in the BRAF gene.
Researchers have found that melanoma patients with a family history of melanoma and/or dysplastic nevi are at high risk of developing multiple primary melanomas. Researchers recommend more intensive follow up for these high-risk patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right